Tarsus Pharmaceuticals, Inc. Common Stock
Follow $TARS
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $TARS by emailVeridion Score
BETAMEDIUM CONF · 5 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is TARS moving today?
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
TARS overview
Related filings and maps
Congress activity in TARS
No receipt-qualified Congressional disclosure is present for TARS in the cached public ledger.
TARS contract awards, year to date.
Public federal awards linked to this ticker.
TARS lobbying filings, year to date.
Registered lobbying filings matched to Tarsus Pharmaceuticals, Inc. Common Stock.